ANIP — ANI Pharmaceuticals, Inc. stock price, charts and financials

NASDAQ·Healthcare·Drug Manufacturers - Specialty & Generic·USA

Latest market price

75.37

-2.88-3.68%

Overview Short InterestFilings

ANIPQT55ANI Pharmaceuticals, Inc.·NASDAQ

Overview Short InterestFilings

75.37-3.68%

Loading chart...

Signal & projected range

Gap down — mean-reversionHistorical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Premium shows the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands ofhistorical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

PRGO-2.53%$12.52 HROW-0.78%$40.13 HCM+0.40%$12.56 PAHC-0.54%$34.11 BHC+3.84%$6.49 ALVO-1.18%$3.77 ETON-2.16%$43.63 RGC-1.17%$5.35

Snapshot

Index	-	P/E	16.20	EPS (ttm)	4.83	Insider Own	24.23%	Shs Outstand	22.73M	Perf Week	-1.25%

Market Cap	1.78B	Forward P/E	7.27	EPS next Y	10.76	Insider Trans	-2.57%	Shs Float	19.42M	Perf Month	-6.60%

Enterprise Value	1.75B	PEG	0.01	EPS next Q	-	Inst Own	-	Short Float	17.36%	Perf Quarter	-6.75%

Income	113.68M	P/S	1.82	EPS this Y	139.88%	Inst Trans	-	Short Ratio	9.82	Perf Half Y	-3.99%

Sales	978.36M	P/B	2.77	EPS next Y	13.85%	ROA	7.08%	Short Interest	3.37M	Perf YTD	-0.87%

Book/sh	-	P/C	8.74	EPS next 5Y	11.56%	ROE	19.19%	52W High	95.84 -21.36%	Perf Year	13.26%

Cash/sh	-	P/FCF	11.16	EPS past 3/5Y	-	ROIC	9.26%	52W Low	65.48 15.11%	Perf 3Y	53.04%

Dividend Est.	-	EV/EBITDA	7.04	Sales past 3/5Y	40.85% 33.53%	Gross Margin	48.28%	Volatility	3.46% 3.06%	Perf 5Y	130.62%

Dividend TTM	-	EV/Sales	1.79	EPS Y/Y TTM	478.85%	Oper. Margin	15.35%	ATR (14)	2.84	Perf 10Y	31.27%

Dividend Ex-Date	-	Quick Ratio	2.41	Sales Y/Y TTM	50.33%	Profit Margin	10.82%	RSI (14)	44.38	Recom	2.30

Dividend Gr. 3/5Y	-	Current Ratio	2.91	EPS Q/Q	20.59%	SMA20	-1.89%	Beta	0.46	Target Price	91.00

Payout	0.33%	Debt/Eq	0.55	Sales Q/Q	20.30%	SMA50	-3.28%	Rel Volume	2.86	Prev Close	78.25

Employees	970	LT Debt/Eq	0.57	Earnings	Nov 06	SMA200	-3.32%	Avg Volume	356.63K	Price	75.37

IPO Date	May 05, 2000	Option/Short	Yes / Yes	EPS/Sales Surpr.	57.84% 14.37%	Net Debt/EBITDA	-0.12	Volume	1,020,050	Change	-3.68%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Jul-16-26	Initiated	Canaccord	Hold	$91
Jan-16-26	Reiterated	Guggenheim	Buy	$114 → $124
Oct-09-25	Reiterated	Truist Securities	Hold	$60 → $90
Sep-17-25	Reiterated	HC Wainwright & Co.	Buy	$94 → $121
Sep-08-25	Reiterated	Guggenheim	Buy	$86 → $114
Aug-08-25	Reiterated	Piper Sandler		$80 → $94
Mar-05-25	Reiterated	Guggenheim	Buy	$86
Sep-18-24	Reiterated	Raymond James	Outperform	$48 → $83
Sep-11-24	Downgrade	Truist Securities	Buy → Hold	$60
Jun-26-24	Reiterated	HC Wainwright & Co.	Buy	$87 → $94

Latest News

Aug-07-26

Aug-07-2602:44PM

ANI Pharmaceuticals, Inc. (ANIP) Q2 2026 Earnings Call Transcriptseekingalpha.com

10:31AM

Compared to Estimates, ANI (ANIP) Q2 Earnings: A Look at Key Metricszacks.com

10:06AM

ANI Pharmaceuticals Q2 Earnings Call Highlightsmarketbeat.com

09:06AM

ANI Pharmaceuticals (ANIP) Q2 Earnings and Revenues Beat Estimateszacks.com

06:50AM

ANI Pharmaceuticals Reports Record Second Quarter 2026 Financial Resultsglobenewswire.com

Aug-06-26

Aug-06-2608:50AM

ANI Pharmaceuticals: The Market Is Pricing The Present, Not The Futureseekingalpha.com

Jul-31-26

Jul-31-2611:01AM

ANI Pharmaceuticals (ANIP) Reports Next Week: Wall Street Expects Earnings Growthzacks.com

Jul-24-26

Jul-24-2606:50AM

ANI Pharmaceuticals to Discuss Second Quarter 2026 Financial Results on August 7, 2026 at 8:00 a.m. ETglobenewswire.com

06:25AM

Two Years to Build or Pay 200% — Which US Pharma Stocks Win?Benzinga

Jul-22-26

Jul-22-2609:16AM

Trump's generic drug tariffs: What they could mean for medicine prices, manufacturers and supplycnbc.com

Jul-21-26

Jul-21-2603:53AM

Bessemer Group Inc. Acquires 19,800 Shares of ANI Pharmaceuticals, Inc. $ANIPdefenseworld.net

Jul-17-26

Jul-17-2606:30AM

Canaccord Genuity Initiates Coverage On ANI Pharmaceuticals with Hold Rating, Announces Price Target of $91Benzinga

Jul-16-26

Jul-16-2604:34PM

ANI Pharmaceuticals Announces Intent to Appeal Rulings in CG Oncology Matterglobenewswire.com

Jul-13-26

Jul-13-2612:55PM

ANI Pharmaceuticals reports Phase 4 data for uveitis eye implantproactiveinvestors.com

06:50AM

ANI Pharmaceuticals Announces Positive Six-Month Topline Data from the Phase 4 Open-Label, Single-Arm SYNCHRONICITY Trial Evaluating Fluocinolone Acetonide Intravitreal Implant in Patients with Chronic Non-Infectious Uveitisglobenewswire.com

Company

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. The company serves its products to national wholesalers, specialty pharmacies, retail pharmacy chains, distributors, mail order houses, group purchasing organizations, and hospitals and healthcare providers. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 12/31/2018
Total Revenue	978	883	614	—	—	—	—	—	—
Cost of Goods Sold Incl. D&A	241	433	250	—	—	—	—	—	—
Gross Profit	473	451	364	—	—	—	—	—	—
Selling, General and Administrative Excl. Other	326	318	250	—	—	—	—	—	—
Research and Development	50	52	45	—	—	—	—	—	—
Other Operating Expense	212	-1	69	—	—	—	—	—	—
Operating Income	150	81	1	—	—	—	—	—	—
Interest Expense	20	20	18	—	—	—	—	—	—
Unusual Expense	—	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	13	35	-5	—	—	—	—	—	—
Net Income Before Taxes	142	96	-22	—	—	—	—	—	—
Income Taxes	34	17	-4	—	—	—	—	—	—
Consolidated Net Income	105	78	-19	—	—	—	—	—	—
Net Income From Continuing Operations	108	78	-19	—	—	—	—	—	—
Net Income	105	78	-19	—	—	—	—	—	—
EPS (Recurring)	4.83	3.50	-1.04	—	—	—	—	—	—
EPS (Basic, Before Extraordinaries)	4.83	3.50	-1.04	—	—	—	—	—	—
EPS (Diluted)	4.63	3.32	-1.04	—	—	—	—	—	—
EBITDA	248	207	63	—	—	—	—	—	—
Other After Tax Adjustments	—	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—	—
Price To Earnings Ratio	16.28	23.78	—	—	—	—	—	—	—
Price To Sales Ratio	1.62	1.79	1.71	—	—	—	—	—	—
Gross Margin	48.36	51.08	59.28	—	—	—	—	—	—
Operating Margin	15.34	9.17	0.16	—	—	—	—	—	—
Net Margin	10.74	8.83	-3.09	—	—	—	—	—	—
Shares Outstanding	21	20	19	—	—	—	—	—	—
Market Capitalization	1,583	1,579	1,050	—	—	—	—	—	—
Operating Lease Expense	—	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
CAREY STEPHEN P.	SVP & CFO	Jul 29 '26	Sale	81.36	2,850	231,876	174,693	Jul 30
Cook Meredith	SR. VP, GENERAL COUNSEL & SEC.	Jul 13 '26	Sale	81.84	500	40,920	77,390	Jul 14
CAREY STEPHEN P.	SVP & CFO	Jul 02 '26	Option Exercise	49.51	3,313	164,027	180,856	Jul 06
CAREY STEPHEN P.	SVP & CFO	Jul 02 '26	Sale	86.00	3,313	284,918	177,543	Jul 06
CAREY STEPHEN P.	SVP & CFO	Jun 29 '26	Sale	84.12	2,850	239,742	177,543	Jun 30
Cook Meredith	SR. VP, GENERAL COUNSEL & SEC.	Jun 12 '26	Sale	82.03	500	41,015	77,890	Jun 15
HAUGHEY THOMAS	Director	Jun 08 '26	Sale	80.88	2,000	161,760	38,878	Jun 10
CAREY STEPHEN P.	SVP & CFO	Jun 05 '26	Option Exercise	49.51	3,312	163,977	183,705	Jun 09
CAREY STEPHEN P.	SVP & CFO	Jun 05 '26	Sale	80.00	3,312	264,960	180,393	Jun 09
Walsh Patrick D	Director	May 13 '26	Sale	80.63	10,000	806,300	38,432	May 13
Cook Meredith	SR. VP, GENERAL COUNSEL & SEC.	May 13 '26	Sale	78.16	500	39,080	78,390	May 13
Gutwerg Ori	SVP, GENERICS	May 12 '26	Sale	79.50	2,772	220,374	78,696	May 13
Rowland Thomas Andrew	SVP, HEAD - ESTABLISHED BRANDS	May 12 '26	Sale	79.21	459	36,357	38,271	May 13
Walsh Patrick D	Director	May 11 '26	Sale	80.75	3,973	320,820	48,432	May 13
Lalwani Nikhil	PRESIDENT & CEO	May 11 '26	Sale	77.57	55,000	4,266,350	349,889	May 13

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.